Drug profile · INN
daptomycin
CUBICIN
daptomycin (CUBICIN) is a cell membrane inhibitor. Associated with MAIA Biotechnology. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — daptomycin
- US status
- approved
- Class
- Antiinfectives for systemic use (J01)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
daptomycin (CUBICIN) is a cell membrane inhibitor. Associated with MAIA Biotechnology. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Cell membrane inhibitor
Primary target: Cell membrane
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is daptomycin?
daptomycin (CUBICIN) is a cell membrane inhibitor. Associated with MAIA Biotechnology. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for daptomycin?
CUBICIN is a marketed brand name for daptomycin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of daptomycin?
daptomycin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.